Medite Cancer Diagnostics Inc MDIT:OTCPK

RT Quote | Exchange | USD
Last | 9:30 AM EST
0.0255quote price arrow up+0.0055 (+27.50%)
Volume
100
52 week range
0.00 - 0.06

...

Loading . . .

KEY STATS

  • Open0.0255
  • Day High0.0255
  • Day Low0.0255
  • Prev Close0.02
  • 52 Week High0.06
  • 52 Week High Date07/15/20
  • 52 Week Low0.00
  • 52 Week Low Date09/23/20
  • Market Cap2.21M
  • Shares Out86.72M
  • 10 Day Average Volume0.00M
  • Dividend-
  • Dividend Yield-
  • Beta1.27
  • 1 Year % Change-36.25

RATIOS/PROFITABILITY

  • EPS (TTM)-0.15
  • P/E (TTM)-0.17
  • Fwd P/E (NTM)-
  • EBITDA (MRQ)-3.732M
  • ROE (MRQ)-86.46%
  • Revenue (MRQ)8.13M
  • Gross Margin (MRQ)23.71%
  • Net Margin (MRQ)-65.49%
  • Debt To Equity (MRQ)89.20%

EVENTS

  • Earnings Date-
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest Medite Cancer Diagnostics Inc News

There is no recent news for this security.

Latest MDIT News From Our Partners

There is no recent news for this security.

QUOTE FINDER

Profile

MORE
MEDITE Cancer Diagnostics, Inc. (MEDITE), formerly CytoCore, Inc., is a medical technology company engaged in the development, engineering, manufacturing and marketing of molecular biomarkers and medical devices and consumables for detection, risk assessment and diagnosis of cancer, precancerous conditions and related diseases. The Company develops, manufactures and sells a range of laboratory devices and consumable supplies for its target market in the histology and cytology...
William Lewis IV
Chairman
Michaela Ott
Chief Operating Officer
Address
414 N Orleans St Ste 502
Chicago, IL
60654-4498
United States